Silence Therapeutics Stock Discussion

$Silence Therapeutics (SLN.US)$
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics presented additional Phase 1 results for divesiran in polycythemia vera (PV) patients at the ASH Annual Meeting. The SANRECO study data showed substantial reduction in phlebotomy frequency and lower hematocrit levels in 19 PV patients. Following treatment, only five phlebotomies were required during t...

$Silence Therapeutics (SLN.US)$ Stock rated a buy and with the lowest PT being $31. Had the same dip last year so it will be around February 21 when it reaches its PT.
$Rezolve AI (RZLV.US)$ Alot of short shares sold this month and in September. Reversal should be starting now that it has reached $1.63. First climb will be to 4.70 with that PT being at the end of December. February's PT will be 12.00. Partnerships with Microsoft and Google will push it until they re...

$Silence Therapeutics (SLN.US)$ Silence Therapeutics Reports Topline Results From Phase 1 Multiple Dose Study Of Zerlasiran; Lp(a) Levels Remained Around 90% Lower Than Baseline At Study Endpoint